Collaborative care for depression in patients with diabetes increased depression-free days and had economic benefit: COMMENTARY
- Collaborative care for depression in patients with diabetes increased depression-free days and had economic benefit. Simon, G. E.; Simon, W. J.; Lin, E. H. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p78
The article presents a study which examines the incremental cost effectiveness of systematic depression treatment in outpatients with diabetes mellitus and depression. Results revealed that patients in the collaborative-care group have a similar number of depression-free days in the first year....
- Cost of Illness: An Ongoing Battle Worth Fighting. Greenberg, Paul // PharmacoEconomics;Dec2014, Vol. 32 Issue 12, p1151
An introduction is presented in which the editor discusses various reports within the issue on topics including cost effectiveness of drugs, mental depression, and pharmacoeconomics.
- Online and Social Networking Interventions for the Treatment of Depression in Young People: A Systematic Review. Rice, Simon M; Goodall1, Joanne; Hetrick, Sarah E; Parker, Alexandra G; Gilbertson, Tamsyn; Amminger, G. Paul; Davey, Christopher G; McGorry, Patrick D; Gleeson, John; Alvarez-Jimenez1, Mario // Journal of Medical Internet Research;Sep2014, Vol. 16 Issue 9, p1
Background: Major depression accounts for the greatest burden of all diseases globally. The peak onset of depression occurs between adolescence and young adulthood, and for many individuals, depression displays a relapse-remitting and increasingly severe course. Given this, the development of...
- Cost-Effectiveness of Collaborative Care for the Treatment of Depressive Disorders in Primary Care: A Systematic Review. Grochtdreis, Thomas; Brettschneider, Christian; Wegener, Annemarie; Watzke, Birgit; Riedel-Heller, Steffi; Härter, Martin; König, Hans-Helmut // PLoS ONE;May2015, Vol. 10 Issue 5, p1
Background: For the treatment of depressive disorders, the framework of collaborative care has been recommended, which showed improved outcomes in the primary care sector. Yet, an earlier literature review did not find sufficient evidence to draw robust conclusions on the cost-effectiveness of...
- Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants. Bosmans, Judith E.; Brook, Oscar H.; van Hout, Hein P. J.; de Bruijne, Martine C.; Nieuwenhuyse, Hugo; Bouter, Lex M.; Stalman, Wim A. B.; van Tulder, Maurits W. // PharmacoEconomics;2007, Vol. 25 Issue 1, p25
INTRODUCTION: The efficacy of antidepressants in the treatment of depression has been convincingly demonstrated in randomised trials. However, non-adherence to antidepressant treatment is common.Patients who came to 19 pharmacies with a new prescription for a non-tricyclic antidepressant, i.e. ...
- Assessing full remission. McIntyre, Roger; Kennedy, Sidney; Bagby, R. Michael; Bakish, David // Journal of Psychiatry & Neuroscience;Jul2002, Vol. 27 Issue 4, p235
Assesses the severity of depression and response to therapy in clinical research. Use of the 17-item Hamilton Rating Scale for Depression; Importance of achieving full remission in minimizing the risk of relapse and recurrence; Shortened form of the 17-item of the HAM-D.
- Escitalopram tops in Belgium. // PharmacoEconomics & Outcomes News;Mar2014, Vol. 697 Issue 1, p5
The article discusses research being done on the cost effectiveness of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium, which references a study by L. Annemans et al. published in the February 20, 2014 issue of "PharmacoEconomics."
- Therapy underused despite range of options in depression. // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p5
Presents information on a study which revealed the underuse of therapeutics for patients with depression in Australia. Characteristics of the patients under study; Enumeration of the strategies; Cost effectiveness of the strategies under Australian health service conditions.
- Escitalopram dominates generic venlafaxine for MDD in Sweden. // PharmacoEconomics & Outcomes News;4/14/2012, Issue 651, p10
The article discusses research on the cost effectiveness of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder in Sweden, referencing a study by G. Nordstrom and colleagues published in the March 2012 issue of "Value in Health."